After migrating into the glioma environment, TAMs tend to possess the M2 phenotype, and their differentiation is driven by the secretion of immunosuppressive factors, including CSF-1, CCL2, IL-4, IL-6, IL-10, and transforming growth factor (TGF- β), from tumor cells (64, 65). Here, CCL2 is linked to glioma.